GSK, Vir's hopes for a Covid-19 an­ti­body fall flat in NIH 'mas­ter pro­to­col' with no ben­e­fit in hos­pi­tal­ized pa­tients

Glax­o­SmithK­line and Vir Biotech­nol­o­gy were hope­ful that one of their part­nered an­ti­bod­ies would carve out a win af­ter get­ting the in­vite to a ma­jor NIH study in hos­pi­tal­ized Covid-19 pa­tients. But just like Eli Lil­ly, the pair’s drug couldn’t hit the mark, and now they’ll be left to take a hard look at the game plan.

The NIH has shut down en­roll­ment for GSK and Vir’s an­ti­body VIR-7831 in its late-stage AC­TIV-3 tri­al af­ter the drug showed neg­li­gi­ble ef­fect in achiev­ing sus­tained re­cov­ery in hos­pi­tal­ized Covid-19 pa­tients, the part­ners said Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER